ACE 031

Description

ACE-031
CAS Number	616204-22-9
Molar Mass	1311.45 g/mol
Chemical Formula	C33H57N11O9
IUPAC Name	UNII-U8DGS69FVC U8DGS69FVC 1621169-52-5 CHEMBL3410227 Myostatin inhibitory peptide 7 BDBM50071379 ACE-031 Myostatin inhibitory peptide 7 Ala-Trp-Arg-Gln-Asn-Thr-Arg-Tyr-Ser-Arg-Ile-Glu-Ala-Ile-Lys-Ile-Gln-Ile-Leu-Ser-Lys-Leu-Arg-Leu-NH2

Introduction

ACE 031 vials represent an advanced research product designed exclusively for scientific inquiry. It is imperative to emphasize that these vials are intended solely for research purposes, and any mention of human consumption is strictly prohibited.

Key Characteristics

Each ACE 031 vial contains a precisely measured quantity of ACE 031, a research peptide investigated for its role in musculoskeletal and metabolic research. The product adheres to stringent quality standards, ensuring accuracy and reliability in research settings.

Research Applications

ACE 031 vials find application in diverse research areas, particularly in musculoskeletal and metabolic studies. Researchers can utilize this product to investigate the physiological effects of ACE 031 in controlled experimental conditions.

Research Benefits

ACE 031 and Energy Metabolism Research

Research suggests a potential link between ACE 031 and energy metabolism. Studies indicate that ACE 031 may play a role in influencing metabolic processes, contributing to enhanced energy utilization.

ACE 031 and Muscle Repair

Preliminary findings propose that ACE 031 may have implications for muscle repair. Research in animal models suggests that ACE 031 could potentially enhance the regenerative capacity of muscles following injury or stress.

ACE 031 and Bone Density:

Exploratory studies indicate potential implications of ACE 031 in bone density research. Investigations suggest that ACE 031 may contribute to increased bone mineral density, offering potential benefits for skeletal health.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

All clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon the finalization of your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer satisfaction is our top priority. Should you find any dissatisfaction with the product received, kindly contact us at 419-707-5450 or email our support team at support@bc9.co.

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References:

1. Relizani K, Mouisel E, Giannesini B, Hourdé C, Patel K, Morales Gonzalez S, Jülich K, Vignaud A, Piétri-Rouxel F, Fortin D, Garcia L, Blot S, Ritvos O, Bendahan D, Ferry A, Ventura-Clapier R, Schuelke M, Amthor H. Blockade of ActRIIB signaling triggers muscle fatigability and metabolic myopathy. Mol Ther. 2014 Aug;22(8):1423-1433. doi: 10.1038/mt.2014.90. Epub 2014 May 27. PMID: 24861054; PMCID: PMC4435590. [Read More]
2. Campbell C, McMillan HJ, Mah JK, Tarnopolsky M, Selby K, McClure T, Wilson DM, Sherman ML, Escolar D, Attie KM. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle Nerve. 2017 Apr;55(4):458-464. doi: 10.1002/mus.25268. Epub 2016 Dec 23. PMID: 27462804. [Read More]
3. Puolakkainen T, Ma H, Kainulainen H, Pasternack A, Rantalainen T, Ritvos O, Heikinheimo K, Hulmi JJ, Kiviranta R. Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy. BMC Musculoskelet Disord. 2017 Jan 19;18(1):20. doi: 10.1186/s12891-016-1366-3. PMID: 28103859; PMCID: PMC5244551. [Read More]